Context Therapeutics® Strengthens Research & Development Team
January 05 2022 - 4:01PM
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:
CNTX), a women’s oncology company developing small molecule and
immunotherapy treatments for breast and gynecological
cancers, today announced the appointments of Christopher Beck
as SVP of Operations and Mark Fletcher, Ph.D., as VP of
R&D. Context also announced the planned retirement of its
current Head of CMC, Bill Rencher, Ph.D., who will move into
an advisory role with the Company.
“Context is in a pivotal phase of growth and change
as we near key inflection points with our pipeline, bolstered by
our recent private placement and initial public offering. As part
of Context’s leadership, Mr. Beck and Dr. Fletcher will help guide
Context’s R&D operations, leveraging their proven knowledge,
capabilities, and leadership skills to help Context achieve its
product development objectives. We celebrate Dr. Rencher’s
distinguished pharmaceutical career and wish him well on his much
deserved retirement,” said Martin Lehr, CEO of Context
Therapeutics. “As we start 2022, we’re pleased with the strong team
we’ve assembled to advance our lead product candidate onapristone
extended release (ONA-XR) in breast, ovarian, and endometrial
cancers, as well as our preclinical anti-claudin 6 bispecific
antibody.”
Mr. Beck joins Context from Galera Therapeutics,
where he served as VP of Program Management. Prior to Galera, Mr.
Beck spent nearly a decade at Shire where he served in roles of
increasing responsiblity and created the company’s first global
project management and resource capacity planning capability.
Throughout his career, Mr. Beck also held management positions at
Merck and AstraZeneca, among others. He holds a B.S. in Information
Technology from Drexel University and a M.B.A. from Penn State
University.
“I’m delighted to join the Context team at this
significant point in the Company’s evolution,” said Mr. Beck. “I
look forward to leading Context’s operational efforts to help it
deliver on the important work to advance medicines for women’s
cancers.”
Prior to joining Context, Dr. Fletcher was VP of
Product Development at Pharmaceutical Associates, Inc. where he led
development, analytical, and regulatory activity. In prior
roles, he served as Head of Non-Injectable R&D for Hikma
Pharmaceutical U.S. Operations, CSO at Douglas Pharmaceuticals, and
VP of Technical Operations and Regulatory Affairs at PBM
Pharmaceuticals. Dr. Fletcher also held senior positions at
Endo Health Solutions (Qualitest) and Ligand Pharmaceuticals, among
others. He holds a B.S. in Pharmacy and a M.S and Ph.D. in
Industrial Pharmacy from University of Maryland.
“There exists a significant unmet need for more
effective treatments for women’s hormone-driven cancers,” said Dr.
Fletcher. “I look forward to collaborating with our internal and
external development partners as we continue to progress the
evaluation of ONA-XR’s potential benefit in the treatment of these
cancers.”
About Context
Therapeutics®Context Therapeutics Inc.
(Nasdaq: CNTX), is a women’s oncology company developing small
molecule and immunotherapy treatments to transform care for breast
and gynecological cancers. The Company’s robust clinical program
for lead candidate onapristone extended release (ONA-XR) comprises
three Phase 2 clinical trials and one Phase 1b/2 clinical trial in
hormone-driven breast, ovarian, and endometrial cancer, as well as
two Phase 0 biomarker pharmacodynamic trials in breast cancer.
ONA-XR is a novel, first-in-class small molecule under development
as a potent and specific antagonist of the progesterone receptor, a
key unchecked mechanism in hormone-driven women’s cancers. Context
is headquartered in Philadelphia, PA. For more information, visit
www.contexttherapeutics.com.
Forward-looking StatementsThis
press release contains “forward-looking statements” that involve
substantial risks and uncertainties for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
Any statements, other than statements of historical fact, included
in this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as "may," "will," "expect," "anticipate," "plan," "intend," and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
forward-looking statements. These include, without limitation,
statements regarding (i) the results of our clinical trials, (ii)
the potential benefits of the product candidates, (iii) the
likelihood data will support future development, (iv) the potential
for our employees and consultants to perform services as
anticipated, and (v) the likelihood of obtaining regulatory
approval of our product candidates. Forward-looking statements in
this release involve substantial risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by the forward-looking statements, and we, therefore cannot
assure you that our plans, intentions, expectations or strategies
will be attained or achieved. Other factors that may cause actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
our filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as otherwise required by law, we disclaim any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Media Contact:Gina Cestari6
Degrees917-797-7904gcestari@6degreespr.com
Investor Relations Contact:Laine
YonkerEdison Grouplyonker@edisongroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Oct 2023 to Oct 2024